A safety / efficacy trial of isotretinoin as a maintenance therapy for newly diagnosed high risk neuroblastoma

Makimoto Atsushi0 个研究点目标入组 25 人开始时间: 2020年9月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Aged between 1 and 18
•2. Histopathological diagnosis with neuroblastoma or ganglioneuroblastoma
•3. Stratified to high risk group according to International Neuroblastoma Risk Grouping System
•4. No progression after primary treatment including chemotherapy, high-dose chemotherapy with hematopoietic stem cell transplantation and radiotherapy
•5. Within 84 days after the most recent hematopoietic stem cell transplantation or the last day of post-transplantation therapy
•6. No severe organ damage to disturb protocol treatment
•7. No active infectious disease
•8. Written informed consent from the patient and/or the guardian

•1. During an active anticancer treatment or planning anticancer treatment except for immunotherapy including dinutuximab
•2. Concomitant malignancy
•3. Allergy to gelatin
•4. Female patient in pregnancy or possible pregnancy, or during breast feeding
•5. Concomitant psychiatric disorders
•6. Complications which would be an obstacle to observe the treatment protocol

发起方

Makimoto Atsushi